Mesoporous silica nanoparticles for diagnostic and therapeutic applications

Abstract

A system for delivering a therapeutic agent to cell or tissue of a subject includes a mesoporous silica iron oxide nanoparticle with one or more therapeutic agents that are contained in a mesoporous silica layer of the nanoparticle and a remote radiofrequency (RF) energy source for applying RF energy to the nanoparticle effective to release the one or more therapeutic agents from the nanoparticle by mechanical tumbling and/or vibration of the nanoparticle, wherein release of the one or more therapeutic agents not caused by a hyperthermic response of the nanoparticle to the RF energy.

1 - 20 . (canceled) 
     
     
         21 : A nanoparticle comprising:
 an iron oxide core;   a layer of mesoporous silica coated over and contiguous with the iron oxide core; and   one or more therapeutic agents that are entirely contained in the mesoporous silica layer of the nanoparticle.   
     
     
         22 : The nanoparticle of  claim 21 , wherein the layer of mesoporous silica includes a plurality of pore openings through the layer providing access to a plurality of pores in the layer of mesoporous silica. 
     
     
         23 : The nanoparticle of  claim 22 , wherein the layer of mesoporous silica defines an exterior surface between the pore openings and side walls within the pores. 
     
     
         24 : The nanoparticle of  claim 21 , wherein the layer of mesoporous silica is substantially spherical. 
     
     
         25 : The nanoparticle of  claim 21 , the nanoparticle further comprising at least one targeting moiety. 
     
     
         26 : The nanoparticle of  claim 25 , wherein the at least one targeting moiety is linked to the exterior surface of the mesoporous silica layer of the nanoparticle. 
     
     
         27 : The nanoparticle of  claim 26 , including multiple targeting moieties, wherein the spacing and location of the targeting moieties on each nanoparticle is controlled to facilitate delivery, targeting, and/or therapeutic efficacy of the nanoparticle when administered to a subject. 
     
     
         28 : The nanoparticle of  claim 21 , the nanoparticle having a diameter of about 50 nm to about 150 nm. 
     
     
         29 : The nanoparticle of  claim 21 , the iron oxide core having a diameter of about 10 nm to about 50 nm. 
     
     
         30 : The nanoparticle of  claim 21 , the one or more therapeutic agents comprising one or more anti-cancer agents. 
     
     
         31 : The nanoparticle of  claim 21 , the one or more therapeutic agents selected from the group consisting of N-(3-(Aminomethyl)benzyl)acetamidine (1400W), ibrutinib, and doxozosin. 
     
     
         32 : The nanoparticle of  claim 31 , the one or more therapeutic agents comprising 1400W and ibrutinib. 
     
     
         33 : The nanoparticle of  claim 32 , the one or more therapeutic agents further comprising doxazosin 
     
     
         34 : The nanoparticle of  claim 21 , wherein externally applying RF energy to the nanoparticle is effective to release the one or more therapeutic agents from the mesoporous silica layer of the nanoparticle by mechanical tumbling and/or vibration of the nanoparticle, and wherein release of the one or more therapeutic agents is not caused by a hyperthermic response of the nanoparticle to the RF energy. 
     
     
         35 : The nanoparticle of  claim 34 , wherein the RF energy is effective to release the one or more therapeutic agents from the mesoporous silica layer of the nanoparticle when applied at a frequency of about 1 kHz to about 50 kHz. 
     
     
         36 : The nanoparticle of  claim 21 , further comprising one or more imaging agents contained in, and/or conjugated to the mesoporous silica layer of the nanoparticle. 
     
     
         37 : A pharmaceutical composition for treating cancer in a subject, the composition comprising a nanoparticle of claim  1 ; and
 a pharmaceutically acceptable carrier.